Evidence map›Paper›PMID 42198319›Full record

ArticlePharmaceutics2026

Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study.

Ana Alarcia-Lacalle, Miguel Ángel Morán-Rodríguez, Laura Morata, Arantxa Isla, Andrés Canut-Blasco, Alicia Rodríguez-Gascón

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ana Alarcia-LacallePharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0003-2970-7766
Miguel Ángel Morán-RodríguezInfectious Disease Division, Araba University Hospital, Osakidetza Basque Health Service, Francisco Leandro de Viana Kalea, 01009 Vitoria-Gasteiz, Spain.ORCID 0000-0002-5854-1497
Laura MorataDepartment of Infectious Diseases, Hospital Clínic of Barcelona, University of Barcelona, Carrer de Villarroel, 170, 08036 Barcelona, Spain.ORCID 0000-0001-5795-0814
Arantxa IslaPharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0001-7575-2715
Andrés Canut-BlascoMicrobiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Bioaraba Health Research Institute, Jose Atxotegi Kalea s/n, 01009 Vitoria-Gasteiz, Spain.ORCID 0000-0003-3836-9906
Alicia Rodríguez-GascónPharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0002-3195-6385

Funding

Basque Government IT1587-22
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AUC/MICcomplex infectionfCmin > MICMonte Carlo simulationoritavancinPK/PD

Identifiers

PMID42198319
PMCPMC13210602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.